HOUSE_OVERSIGHT_024012.jpg
2.48 MB
Extraction Summary
5
People
12
Organizations
1
Locations
0
Events
3
Relationships
3
Quotes
Document Information
Type:
Investment memorandum / executive summary
File Size:
2.48 MB
Summary
This document is an Executive Summary for 'New Leaf Ventures III, L.P.' (NLV-III), a healthcare technology investment fund targeting $375 million in capital commitments. It details the history of the management company, New Leaf Venture Partners, outlining previous funds (NLV-I and NLV-II) and their affiliation with Sprout Group/Credit Suisse. The document lists the Managing Directors and outlines the fund's strategy to invest in 24-28 U.S.-based healthcare companies. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a congressional document production.
People (5)
| Name | Role | Context |
|---|---|---|
| Philippe Chambon | Managing Director |
MD PhD, Managing Director of NLV-III
|
| Jeani Delagardelle | Managing Director |
Managing Director of NLV-III
|
| Ron Hunt | Managing Director |
Managing Director of NLV-III
|
| Vijay Lathi | Managing Director |
Managing Director of NLV-III
|
| Liam Ratcliffe | Managing Director |
MD PhD, Managing Director of NLV-III
|
Locations (1)
| Location | Context |
|---|---|
Relationships (3)
NLV-III is being formed by New Leaf Venture Partners, L.L.C.
Sprout Group is a venture capital affiliate of Credit Suisse
Have worked together for 15 years over six prior funds
Key Quotes (3)
"The Fund is targeting aggregate capital commitments from limited partners of $375 million."Source
HOUSE_OVERSIGHT_024012.jpg
Quote #1
"NLV-III will be the seventh private equity fund focused on venture and growth stage investments in healthcare and life sciences companies raised by the partners of New Leaf."Source
HOUSE_OVERSIGHT_024012.jpg
Quote #2
"The Fund will seek to invest in a diversified portfolio composed of an estimated 24 to 28 healthcare technology companies, most of which will be U.S. based"Source
HOUSE_OVERSIGHT_024012.jpg
Quote #3
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document